Integrated Cancer Treatment in the Course of Metastatic Pancreatic Cancer: Complete Resolution in 2 Cases
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2018-02-25 / Integr Cancer Ther 2018 09;17(3):994-999Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
/in International Publications, Pancreatic Cancer /von 2017-12-01 / Ann. Oncol. 2017 Dec;28(12):2950-2961The clinical benefit of hyperthermia in pancreatic cancer: a systematic review
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2017-11-23 / Int J Hyperthermia 2018 11;34(7):969-979Dendritic cells based immunotherapy
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications, Pancreatic Cancer /von 2017-10-01 / Am J Cancer Res 2017;7(10):2091-2102Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity
/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2017-09-13 / Int. J. Cancer 2017 12;141(12):2505-2516Retrospective Clinical Study of Advanced Pancreatic Cancer Treated With Chemotherapy and Abdominal Hyperthermia
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2017-07-25 / J Glob Oncol 2018 Sep;4:1-4A phase III, double-blind, randomized clinical trial comparing S-1 in combination with DC vaccine loaded with WT1 peptides (TLP0-001) or placebo for the patients with advanced pancreatic cancer refractory to standard chemotherapy.
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2017-06-03 / J Clin Oncol 35, 2017 (suppl; abstr TPS4153)The Role of Radiofrequency Hyperthermia in The Radiosensitization of A Human Prostate Cancer Cell Line
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2017-05-17 / Cell J 2017;19(Suppl 1):86-95Enhanced DNA Damages of Human Prostate Cancer Cells Induced by Radiofrequency Capacitive Hyperthermia Pre- and Post X-rays: 6 MV versus 15 MV
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2017-05-17 / Cell J 2017;19(Suppl 1):79-85
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de